SCHEMBL2332022

SCHEMBL2332022

COc1cc(CN(CC(O)CO)S(=O)(=O)c2ccc(Cl)cc2)ccc1OCCc1scnc1C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.39
TAS2R14 Q9NYV8 3/20 0.39
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
LMNA P02545 3/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
HTT P42858 2/20 0.38
TSHR P16473 1/20 0.38
BDKRB1 P46663 1/20 0.37
PTGER1 P34995 1/20 0.37
HPGD P15428 1/20 0.37
MMP1 P03956 1/20 0.36
MMP7 P09237 1/20 0.36
MMP8 P22894 1/20 0.36
MMP12 P39900 1/20 0.36
MMP13 P45452 1/20 0.36
BACE1 P56817 2/20 0.36
HIF1A Q16665 1/20 0.36
EPAS1 Q99814 1/20 0.36
THRB P10828 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2338098 0.92 ALDH1A1 (0.40) ALDH1A1TAS2R14MEN1KMT2ALMNA
SCHEMBL2334778 0.88 LMNA (0.41) ALDH1A1TAS2R14MEN1KMT2ALMNA
SCHEMBL2339348 0.88 ALDH1A1 (0.43) ALDH1A1TAS2R14MEN1KMT2ALMNA
SCHEMBL2339713 0.88 MEN1 (0.41) ALDH1A1TAS2R14MEN1KMT2ALMNA
SCHEMBL2333362 0.87 HIF1A (0.46) ALDH1A1TAS2R14MEN1KMT2ALMNA
SCHEMBL2338966 0.86 MEN1 (0.42) ALDH1A1TAS2R14MEN1KMT2ALMNA
SCHEMBL2335244 0.86 TP53 (0.44) ALDH1A1TAS2R14LMNASMN1; SMN2HPGD
SCHEMBL2337909 0.86 ALDH1A1 (0.44) ALDH1A1TAS2R14MEN1KMT2ALMNA
SCHEMBL5668449 0.85 MEN1 (0.40) ALDH1A1TAS2R14MEN1KMT2ALMNA
SCHEMBL2332019 0.85 HIF1A (0.45) ALDH1A1TAS2R14MEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120270902-A1 N-substituted benzene sulfonamides ELAN PHARMACEUTICALS, INC. (US) 2012-10-25 US claimed
EP-2360142-A1 N-substituted benzene sulfonamides Elan Pharmaceuticals Inc. (US) 2011-08-24 EP claimed
EP-1723102-A2 N-SUBSTITUTED BENZENE SULFONAMIDES Elan Pharmaceuticals, Inc. (US) 2006-11-22 EP claimed
US-20050245573-A1 N-substituted benzene sulfonamides ELAN PHARMACEUTICALS, INC. 2005-11-03 US claimed
WO-2005090296-A2 N-SUBSTITUTED BENZENE SULFONAMIDES ELAN PHARMACEUTICALS, INC. (US) 2005-09-29 WO claimed
US-20120270902-A1 N-substituted benzene sulfonamides ELAN PHARMACEUTICALS, INC. (US) 2012-10-25 US disclosed
US-8193389-B2 N-substituted benzene sulfonamides ELAN PHARMACEUTICALS, INC. (US) 2012-06-05 US disclosed
EP-2374792-A1 N-substituted benzene sulfonamides Elan Pharmaceuticals Inc. (US) 2011-10-12 EP disclosed
EP-2360142-A1 N-substituted benzene sulfonamides Elan Pharmaceuticals Inc. (US) 2011-08-24 EP disclosed
EP-1723102-A2 N-SUBSTITUTED BENZENE SULFONAMIDES Elan Pharmaceuticals, Inc. (US) 2006-11-22 EP disclosed
US-20050245573-A1 N-substituted benzene sulfonamides ELAN PHARMACEUTICALS, INC. 2005-11-03 US disclosed
WO-2005090296-A2 N-SUBSTITUTED BENZENE SULFONAMIDES ELAN PHARMACEUTICALS, INC. (US) 2005-09-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245573-A1 N-substituted benzene sulfonamides PSEN1, PSEN2, BCHE ALDH1A1 665/4885TAS2R14 1740/4885MEN1 2523/4885
US-20120270902-A1 N-substituted benzene sulfonamides PSEN1, PSEN2, BCHE ALDH1A1 665/4885TAS2R14 1740/4885MEN1 2523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.